Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Vasculitis Treatment Market by Drug Class (Biologics, Corticosteroids and immunosuppressants), by Disease Type (Small and medium vessel vasculitis, Large vessel vasculitis), by Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

A03183

Pages: 275

Charts: 59

Tables: 149

Vasculitis Treatment Market Research, 2031

The global vasculitis treatment market was valued at $250.1 million in 2021, and is projected to reach $350.1 million by 2031, growing at a CAGR of 3.4% from 2022 to 2031. Vasculitis is defined as the inflammation of the blood vessels such as veins, capillaries and arteries. Inflammation may cause blood vessel walls to thicken, decreasing the diameter of the blood vessel's entry. The various types of vasculitis are grouped according to the size of the blood vessels they affect. There are several side effects that might arise from blood vessel inflammation, including blockage of blood flow, which could render organ damage. Some of the symptoms that have been identified are fatigue, weakness, weight loss, muscle soreness, congestive heart failure, and malaise. Numerous medications are used as therapy options, including corticosteroids, immunosuppressants, and cytotoxic agents.

[COVIDIMPACTSTATEMENT]

Get more information on this report : Request Sample Pages

The vasculitis treatment market is expanding as there is upsurge in vasculitis prevalence and its treatment. In addition, the rise in prevalence of chronic diseases, which has increased demand for vasculitis drugs is anticipated to fuel the growth of the vasculitis treatment market. Proteins that regulate the function of other proteins and cellular processes can be found in biologic goods, as can genes that direct the creation of essential proteins, modified human hormones, or cells that create substances that either stimulate or suppress immune system components. There is active research and development going on in the biologics sector. The success rates of clinical trials for biologics have increased as a result of these research and development efforts. 

Moreover, increase in adoption rate of biologics, and its development by key players favors vasculitis treatment market opportunity. Increase in corticosteroids consumption has directly had a beneficial impact on the market as a result of expanding healthcare access and industry advancements. However, the potential negative effects of using corticosteroids is expected to restrain the vasculitis treatment market growth.

The per capita income of individuals in developing countries has increased, which is escalating the sale of products, thereby boosting the growth of the market. The revenue generated from developing countries has increased considerably over the years, owing to a rise in awareness toward immunosuppressant drugs. Moreover, the improving access to healthcare coupled with developments in the healthcare sector has increased the consumption of drugs, thereby directly creating a positive impact on the market.


Impact of COVID-19
The COVID-19 pandemic is predicted to have a negative impact on the growth of the global vasculitis treatment market in the short term. Moreover, throughout the pandemic, due to the recommendations to maintain social distance, many individuals treated their illnesses via self-medication or other unconventional methods. However, due to decrease in COVID patients, the market is anticipated to rise during the vasculitis treatment market forecast.

Vasculitis treatment market segmentation

The global vasculitis treatment market is segmented on the basis of drug class, disease type, distribution channel, and region. According to drug class, the market is categorized into biologics and corticosteroids & immunosuppressants. By disease type, it is divided into small & medium vessel vasculitis, and large vessel vasculitis. Small & medium vessel vasculitis is further bifurcated as ANCA associated vasculitis and others. As per distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment review
According to drug class, the market is segmented into biologics and corticosteroids & immunosuppressants. The corticosteroids & immunosuppressants segment dominated the vasculitis treatment market size in 2021, owing to increase in usage of corticosteroids in the past decade due to its easy availability and cost effectiveness. The biologics segment is expected to witness highest CAGR during the forecast period, owing to side effects associated with the usage of corticosteroids and R&D in new biologics.

[DRUGCLASSGRAPH]

By disease type, the market is divided into small & medium vessel vasculitis, and large vessel vasculitis. The small & medium vessel vasculitis segment dominated the vasculitis treatment market size in 2021, and is expected to witness highest CAGR during the forecast period owing to higher incidence of vasculitis diseases as well as the availability of treatment for them.  

[DISEASETYPEGRAPH]

By distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the vasculitis treatment market share in 2021, owing to availability of all medications used in hospitals and the reimbursement policies in developing countries, which pay for the high prices of vasculitis medications. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period, owing to maintenance of treatment for a longer duration and easy availability of drugs. 

[DISTRIBUTIONCHANNELGRAPH]

North America accounted for a majority of the global vasculitis treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in vasculitis treatment industry, and presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, development of healthcare infrastructure, and increase in investments projects in the region.

[REGIONGRAPH]

The major players profiled in the vasculitis treatment industry report are AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, InflaRx NV, Novartis AG, Pfizer Inc., Staidson Biopharma Inc., and Teva Pharmaceuticals Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vasculitis treatment market analysis from 2021 to 2031 to identify the prevailing vasculitis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vasculitis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vasculitis treatment market trends, key players, market segments, application areas, and market growth strategies.

 Key Market Segments

  • By Distribution Channel
    • Hospital pharmacies
    • Drug store and retail pharmacies
    • Online Pharmacies
  • By Drug Class
    • Corticosteroids and immunosuppressants
    • Biologics
  • By Disease Type
    • Small and medium vessel vasculitis
      • Type
        • ANCA associated vasculitis
        • Others
    • Large vessel vasculitis
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest Of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest Of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest Of LAMEA

 
Key Market Players

  • Pfizer Inc.
  • AstraZeneca plc
  • Novartis AG
  • InflaRx N.V
  • F. Hoffmann-La Roche Ltd
  • Amneal Pharmaceuticals, Inc.
  • ChemoCentryx
  • AbbVie
  • Teva Pharmaceutical Industries Ltd.
  • Glaxosmithkline plc

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

    • 3.7.Patent Landscape

  • CHAPTER 4: VASCULITIS TREATMENT MARKET, BY DRUG CLASS

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Biologics

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Corticosteroids and immunosuppressants

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

  • CHAPTER 5: VASCULITIS TREATMENT MARKET, BY DISEASE TYPE

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Small and medium vessel vasculitis

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

      • 5.2.4 Small and medium vessel vasculitis Vasculitis Treatment Market by Type

        • 5.2.4.1 ANCA associated vasculitis Market size and forecast, by region
        • 5.2.4.2 Others Market size and forecast, by region

    • 5.3 Large vessel vasculitis

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

  • CHAPTER 6: VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Hospital pharmacies

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Drug store and retail pharmacies

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

    • 6.4 Online Pharmacies

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market analysis by country

  • CHAPTER 7: VASCULITIS TREATMENT MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Drug Class

      • 7.2.3 North America Market size and forecast, by Disease Type

        • 7.2.3.1 North America Small and medium vessel vasculitis Vasculitis Treatment Market by Type

      • 7.2.4 North America Market size and forecast, by Distribution Channel

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Market size and forecast, by Drug Class
          • 7.2.5.1.2 Market size and forecast, by Disease Type
          • 7.2.5.1.3 Market size and forecast, by Distribution Channel
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Market size and forecast, by Drug Class
          • 7.2.5.2.2 Market size and forecast, by Disease Type
          • 7.2.5.2.3 Market size and forecast, by Distribution Channel
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Market size and forecast, by Drug Class
          • 7.2.5.3.2 Market size and forecast, by Disease Type
          • 7.2.5.3.3 Market size and forecast, by Distribution Channel

    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Drug Class

      • 7.3.3 Europe Market size and forecast, by Disease Type

        • 7.3.3.1 Europe Small and medium vessel vasculitis Vasculitis Treatment Market by Type

      • 7.3.4 Europe Market size and forecast, by Distribution Channel

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Market size and forecast, by Drug Class
          • 7.3.5.1.2 Market size and forecast, by Disease Type
          • 7.3.5.1.3 Market size and forecast, by Distribution Channel
        • 7.3.5.2 France
          • 7.3.5.2.1 Market size and forecast, by Drug Class
          • 7.3.5.2.2 Market size and forecast, by Disease Type
          • 7.3.5.2.3 Market size and forecast, by Distribution Channel
        • 7.3.5.3 UK
          • 7.3.5.3.1 Market size and forecast, by Drug Class
          • 7.3.5.3.2 Market size and forecast, by Disease Type
          • 7.3.5.3.3 Market size and forecast, by Distribution Channel
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Market size and forecast, by Drug Class
          • 7.3.5.4.2 Market size and forecast, by Disease Type
          • 7.3.5.4.3 Market size and forecast, by Distribution Channel
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Market size and forecast, by Drug Class
          • 7.3.5.5.2 Market size and forecast, by Disease Type
          • 7.3.5.5.3 Market size and forecast, by Distribution Channel
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Market size and forecast, by Drug Class
          • 7.3.5.6.2 Market size and forecast, by Disease Type
          • 7.3.5.6.3 Market size and forecast, by Distribution Channel

    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class

      • 7.4.3 Asia-Pacific Market size and forecast, by Disease Type

        • 7.4.3.1 Asia-Pacific Small and medium vessel vasculitis Vasculitis Treatment Market by Type

      • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 Japan
          • 7.4.5.1.1 Market size and forecast, by Drug Class
          • 7.4.5.1.2 Market size and forecast, by Disease Type
          • 7.4.5.1.3 Market size and forecast, by Distribution Channel
        • 7.4.5.2 China
          • 7.4.5.2.1 Market size and forecast, by Drug Class
          • 7.4.5.2.2 Market size and forecast, by Disease Type
          • 7.4.5.2.3 Market size and forecast, by Distribution Channel
        • 7.4.5.3 India
          • 7.4.5.3.1 Market size and forecast, by Drug Class
          • 7.4.5.3.2 Market size and forecast, by Disease Type
          • 7.4.5.3.3 Market size and forecast, by Distribution Channel
        • 7.4.5.4 Australia
          • 7.4.5.4.1 Market size and forecast, by Drug Class
          • 7.4.5.4.2 Market size and forecast, by Disease Type
          • 7.4.5.4.3 Market size and forecast, by Distribution Channel
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Market size and forecast, by Drug Class
          • 7.4.5.5.2 Market size and forecast, by Disease Type
          • 7.4.5.5.3 Market size and forecast, by Distribution Channel
        • 7.4.5.6 Rest of Asia-Pacific
          • 7.4.5.6.1 Market size and forecast, by Drug Class
          • 7.4.5.6.2 Market size and forecast, by Disease Type
          • 7.4.5.6.3 Market size and forecast, by Distribution Channel

    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Drug Class

      • 7.5.3 LAMEA Market size and forecast, by Disease Type

        • 7.5.3.1 LAMEA Small and medium vessel vasculitis Vasculitis Treatment Market by Type

      • 7.5.4 LAMEA Market size and forecast, by Distribution Channel

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Market size and forecast, by Drug Class
          • 7.5.5.1.2 Market size and forecast, by Disease Type
          • 7.5.5.1.3 Market size and forecast, by Distribution Channel
        • 7.5.5.2 Saudi Arabia
          • 7.5.5.2.1 Market size and forecast, by Drug Class
          • 7.5.5.2.2 Market size and forecast, by Disease Type
          • 7.5.5.2.3 Market size and forecast, by Distribution Channel
        • 7.5.5.3 South Africa
          • 7.5.5.3.1 Market size and forecast, by Drug Class
          • 7.5.5.3.2 Market size and forecast, by Disease Type
          • 7.5.5.3.3 Market size and forecast, by Distribution Channel
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Market size and forecast, by Drug Class
          • 7.5.5.4.2 Market size and forecast, by Disease Type
          • 7.5.5.4.3 Market size and forecast, by Distribution Channel

  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 Amneal Pharmaceuticals, Inc.

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 AstraZeneca plc

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 F. Hoffmann-La Roche Ltd

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 Glaxosmithkline plc

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 Pfizer Inc.

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 InflaRx N.V

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 Novartis AG

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 ChemoCentryx

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 AbbVie

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 Teva Pharmaceutical Industries Ltd.

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 2. VASCULITIS TREATMENT MARKET, FOR BIOLOGICS, BY REGION, 2021-2031 ($MILLION)
    TABLE 3. VASCULITIS TREATMENT MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 4. VASCULITIS TREATMENT MARKET, FOR CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS, BY REGION, 2021-2031 ($MILLION)
    TABLE 5. VASCULITIS TREATMENT MARKET FOR CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 7. VASCULITIS TREATMENT MARKET, FOR SMALL AND MEDIUM VESSEL VASCULITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 8. VASCULITIS TREATMENT MARKET FOR SMALL AND MEDIUM VESSEL VASCULITIS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 9. GLOBAL SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 10. VASCULITIS TREATMENT MARKET, FOR ANCA ASSOCIATED VASCULITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 11. VASCULITIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 12. VASCULITIS TREATMENT MARKET, FOR LARGE VESSEL VASCULITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 13. VASCULITIS TREATMENT MARKET FOR LARGE VESSEL VASCULITIS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 15. VASCULITIS TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 16. VASCULITIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 17. VASCULITIS TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 18. VASCULITIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 19. VASCULITIS TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 20. VASCULITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 21. VASCULITIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 22. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 23. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 24. NORTH AMERICA SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 25. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 26. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 27. U.S. VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 28. U.S. VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 29. U.S. VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 30. CANADA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 31. CANADA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 32. CANADA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 33. MEXICO VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 34. MEXICO VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 35. MEXICO VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 36. EUROPE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 37. EUROPE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 38. EUROPE SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 39. EUROPE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 40. EUROPE VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 41. GERMANY VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 42. GERMANY VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 43. GERMANY VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 44. FRANCE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 45. FRANCE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 46. FRANCE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 47. UK VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 48. UK VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 49. UK VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 50. ITALY VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 51. ITALY VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 52. ITALY VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 53. SPAIN VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 54. SPAIN VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 55. SPAIN VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 56. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 57. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 58. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 59. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 60. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 61. ASIA-PACIFIC SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 62. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 63. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 64. JAPAN VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 65. JAPAN VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 66. JAPAN VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 67. CHINA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 68. CHINA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 69. CHINA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 70. INDIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 71. INDIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 72. INDIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 73. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 74. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 75. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 76. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 77. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 78. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 79. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 80. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 81. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 82. LAMEA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 83. LAMEA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 84. LAMEA SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 85. LAMEA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 86. LAMEA VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 87. BRAZIL VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 88. BRAZIL VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 89. BRAZIL VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 90. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 91. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 92. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 93. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 94. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 95. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 96. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 97. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 98. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 99.AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
    TABLE 100.AMNEAL PHARMACEUTICALS, INC.: OPERATING SEGMENTS
    TABLE 101.AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
    TABLE 102.AMNEAL PHARMACEUTICALS, INC.: NET SALES,
    TABLE 103.AMNEAL PHARMACEUTICALS, INC.: KEY STRATERGIES
    TABLE 104.ASTRAZENECA PLC: COMPANY SNAPSHOT
    TABLE 105.ASTRAZENECA PLC: OPERATING SEGMENTS
    TABLE 106.ASTRAZENECA PLC: PRODUCT PORTFOLIO
    TABLE 107.ASTRAZENECA PLC: NET SALES,
    TABLE 108.ASTRAZENECA PLC: KEY STRATERGIES
    TABLE 109.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
    TABLE 110.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
    TABLE 111.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
    TABLE 112.F. HOFFMANN-LA ROCHE LTD: NET SALES,
    TABLE 113.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
    TABLE 114.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
    TABLE 115.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
    TABLE 116.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
    TABLE 117.GLAXOSMITHKLINE PLC: NET SALES,
    TABLE 118.GLAXOSMITHKLINE PLC: KEY STRATERGIES
    TABLE 119.PFIZER INC.: COMPANY SNAPSHOT
    TABLE 120.PFIZER INC.: OPERATING SEGMENTS
    TABLE 121.PFIZER INC.: PRODUCT PORTFOLIO
    TABLE 122.PFIZER INC.: NET SALES,
    TABLE 123.PFIZER INC.: KEY STRATERGIES
    TABLE 124.INFLARX N.V: COMPANY SNAPSHOT
    TABLE 125.INFLARX N.V: OPERATING SEGMENTS
    TABLE 126.INFLARX N.V: PRODUCT PORTFOLIO
    TABLE 127.INFLARX N.V: NET SALES,
    TABLE 128.INFLARX N.V: KEY STRATERGIES
    TABLE 129.NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 130.NOVARTIS AG: OPERATING SEGMENTS
    TABLE 131.NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 132.NOVARTIS AG: NET SALES,
    TABLE 133.NOVARTIS AG: KEY STRATERGIES
    TABLE 134.CHEMOCENTRYX: COMPANY SNAPSHOT
    TABLE 135.CHEMOCENTRYX: OPERATING SEGMENTS
    TABLE 136.CHEMOCENTRYX: PRODUCT PORTFOLIO
    TABLE 137.CHEMOCENTRYX: NET SALES,
    TABLE 138.CHEMOCENTRYX: KEY STRATERGIES
    TABLE 139.ABBVIE: COMPANY SNAPSHOT
    TABLE 140.ABBVIE: OPERATING SEGMENTS
    TABLE 141.ABBVIE: PRODUCT PORTFOLIO
    TABLE 142.ABBVIE: NET SALES,
    TABLE 143.ABBVIE: KEY STRATERGIES
    TABLE 144.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
    TABLE 145.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
    TABLE 146.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
    TABLE 147.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
    TABLE 148.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

  • LIST OF FIGURES

  • FIGURE 1.VASCULITIS TREATMENT MARKET SEGMENTATION
    FIGURE 2.VASCULITIS TREATMENT MARKET,2021-2031
    FIGURE 3.VASCULITIS TREATMENT MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.VASCULITIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.PATENT ANALYSIS BY COMPANY
    FIGURE 13.PATENT ANALYSIS BY COUNTRY
    FIGURE 14.VASCULITIS TREATMENT MARKET,BY DRUG CLASS,2021(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF BIOLOGICS VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 17.VASCULITIS TREATMENT MARKET,BY DISEASE TYPE,2021(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LARGE VESSEL VASCULITIS VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 20.VASCULITIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES VASCULITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 24.VASCULITIS TREATMENT MARKET BY REGION,2021
    FIGURE 25.U.S. VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 26.CANADA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 27.MEXICO VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 28.GERMANY VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 29.FRANCE VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 30.UK VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 31.ITALY VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 32.SPAIN VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 33.REST OF EUROPE VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 34.JAPAN VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 35.CHINA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 36.INDIA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 37.AUSTRALIA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 38.SOUTH KOREA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 39.REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 40.BRAZIL VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 41.SAUDI ARABIA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 42.SOUTH AFRICA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 43.REST OF LAMEA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 48.COMPETITIVE DASHBOARD
    FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 50.AMNEAL PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
    FIGURE 51.ASTRAZENECA PLC.: NET SALES ,($MILLION)
    FIGURE 52.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
    FIGURE 53.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
    FIGURE 54.PFIZER INC..: NET SALES ,($MILLION)
    FIGURE 55.INFLARX N.V.: NET SALES ,($MILLION)
    FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
    FIGURE 57.CHEMOCENTRYX.: NET SALES ,($MILLION)
    FIGURE 58.ABBVIE.: NET SALES ,($MILLION)
    FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)

Purchase Full Report of
Vasculitis Treatment Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved